Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	May 26, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	0.01	-0.06	-0.11	-0.14
Debt / FCF Ratio	-	-	-	0.18
Net Debt / Equity Ratio	-1.13	-0.06	-0.11	-0.14
Net Debt / EBITDA Ratio	4.49	-0.07	-0.52	-1.58
Net Debt / FCF Ratio	4.10	-0.09	-0.30	0.18
Asset Turnover	-	2.40	1.25	-
Quick Ratio	12.91	0.00	-	0.02
Current Ratio	13.04	0.07	0.02	0.03
Return on Assets (ROA)	-	-399.25%	-94.53%	-
Return on Capital Employed (ROCE)	-22.00%	148.40%	67.40%	27.20%

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.